ライフサイエンスコーパス: sigmoidoscopy

1 All subjects underwent a visceral stressor (sigmoidoscopy).

2 ity: fecal occult blood testing and flexible sigmoidoscopy.

3 val for colorectal cancer (CRC) screening by sigmoidoscopy.

4 blood testing (FOBT), but not about flexible sigmoidoscopy.

5 had been adequately examined at the initial sigmoidoscopy.

6 d the use of fecal occult blood testing plus sigmoidoscopy.

7 creening with a fecal occult-blood test plus sigmoidoscopy.

8 f these neoplasms would not be detected with sigmoidoscopy.

9 enhancing provider utilization of screening sigmoidoscopy.

10 new Medicare reimbursement rate for flexible sigmoidoscopy.

11 ic tubular adenomas (TAs) found at screening sigmoidoscopy.

12 olon following a positive screening flexible sigmoidoscopy.

13 control studies support the use of screening sigmoidoscopy.

14 distal adenomas or cancers found at flexible sigmoidoscopy.

15 e screening with fecal occult blood tests or sigmoidoscopy.

16 k relative first, and $3208 for conventional sigmoidoscopy.

17 he size and number of distal polyps found by sigmoidoscopy.

18 copy (aOR, 0.57; 95% CI, 0.47-0.70), but not sigmoidoscopy.

19 o, 0.47; 95% CI, 0.29 to 0.76) but not after sigmoidoscopy.

20 40 674 (71%) people underwent flexible sigmoidoscopy.

21 es and are 10-fold less common with flexible sigmoidoscopy.

22 Of 3496 consecutive patients referred for sigmoidoscopy, 311 had neoplastic rectosigmoid polyps; 1

23 crease to approximately 9.5 million flexible sigmoidoscopies (95% CI, 8.4-10.5) and 22.4 million colo

24 Among 4490 patients who underwent sigmoidoscopy, a neoplastic lesion was detected in 401 (

25 blood test screening plus periodic flexible sigmoidoscopy about every 5 years for asymptomatic, aver

26 At the time of sigmoidoscopy, all polyps were biopsied and characterize

27 If flexible sigmoidoscopy alone had been performed, advanced neoplas

28 ere nonsignificantly more likely to complete sigmoidoscopy alone or in combination with another test

29 Neither DCBE nor rigid sigmoidoscopy alone was sufficiently sensitive to be use

30 ns identified if they had undergone flexible sigmoidoscopy alone, as compared with 66.3 percent of ma

31 en identified if they had undergone flexible sigmoidoscopy alone.

32 onal life-year gained compared with flexible sigmoidoscopy alone.

33 ately 2.8 million (95% CI, 2.4-3.1) flexible sigmoidoscopies and 14.2 million (95% CI, 12.1-16.4) col

34 Approximately 2.8 million flexible sigmoidoscopies and 14.2 million colonoscopies were esti

35 s performed 24.9% (95% CI, 20.3-29.5) of all sigmoidoscopies and 2.0% (95% CI, 1.4-2.6) of all colono

36 d perform an additional 6.7 million flexible sigmoidoscopies and 8.2 million colonoscopies in 1 year.

37 confidence interval [CI], 37.2-50.2) of all sigmoidoscopies and 82.5% (95% CI, 80.3-84.7) of all col

38 0.59 (95% CI, 0.45 to 0.76) after screening sigmoidoscopy and 0.32 (95% CI, 0.24 to 0.45) after scre

39 oup (10,283 randomized to receive a flexible sigmoidoscopy and 10,289 to receive flexible sigmoidosco

40 on group), 83.5% underwent baseline flexible sigmoidoscopy and 54.0% were screened at 3 or 5 years.

41 Rigid sigmoidoscopy and an anorectal examination were also use

42 the end of the treatment period was based on sigmoidoscopy and clinical scores.

43 e size and histology of polyps identified by sigmoidoscopy and colonoscopy were noted.

44 icacy, including fecal occult blood testing, sigmoidoscopy and colonoscopy.

45 cancer and cancer precursor lesions include sigmoidoscopy and colonoscopy.

46 3 years for FOBT and 5, 10, or 20 years for sigmoidoscopy and colonoscopy.

47 doscopy or combination of once-only flexible sigmoidoscopy and fecal occult blood testing (FOBT).

48 flexible sigmoidoscopy screening or flexible sigmoidoscopy and FOBT reduced colorectal cancer inciden

49 flexible sigmoidoscopy only vs the flexible sigmoidoscopy and FOBT screening groups.

50 sigmoidoscopy and 10,289 to receive flexible sigmoidoscopy and FOBT).

51 Controls (n = 228) were screened with sigmoidoscopy and found not to have colorectal adenomas.

52 atment, there was significant improvement in sigmoidoscopy and histopathology scores in the budesonid

53 ntrol studies supported the effectiveness of sigmoidoscopy and possibly colonoscopy in reducing colon

54 eated a new library of 57 videos of flexible sigmoidoscopy and stratified them based on disease sever

55 tegies included conventional serial flexible sigmoidoscopy and two different APC gene testing approac

56 , 0.60 (95% CI, 0.53 to 0.68) after negative sigmoidoscopy, and 0.44 (95% CI, 0.38 to 0.52) after neg

57 ance of fecal occult blood testing, flexible sigmoidoscopy, and barium enema.

58 ealth plan members had colonoscopy, flexible sigmoidoscopy, and DCBE less often (ratio of change, 0.7

59 ect to the deductible (colonoscopy, flexible sigmoidoscopy, and DCBE).

60 Incidence rates of colonoscopy, flexible sigmoidoscopy, and fecal occult blood test were 27.9, 0.

61 endoscopists may perform screening flexible sigmoidoscopy as safely and as effectively as gastroente

62 ormance of endoscopic ultrasound or flexible sigmoidoscopy at 3- to 6-month intervals for the first 2

63 men and women aged 50-75 years who underwent sigmoidoscopy at a health maintenance organization in so

64 s (colonoscopy indicated up to age 77 years, sigmoidoscopy at age 78 years, and FIT at ages 79 and 80

65 s (colonoscopy indicated up to age 80 years, sigmoidoscopy at age 81 years, and FIT at ages 82 and 83

66 Participants received flexible sigmoidoscopy at baseline and 3 or 5 y after.

67 ncluded no evaluation, colonoscopy, flexible sigmoidoscopy, barium enema, anoscopy, or any feasible c

68 The cost of flexible sigmoidoscopy-based screening for colorectal cancer coul

69 and 363 control subjects from this previous sigmoidoscopy-based study.

70 men would be missed with the use of flexible sigmoidoscopy but detected by colonoscopy.

71 Sigmoidoscopy by an endoscopist blinded to treatment ass

72 pared on receipt of screening colonoscopy or sigmoidoscopy by using conditional logistic regression t

73 ctal cancer with fecal occult blood tests or sigmoidoscopy can reduce mortality rates.

74 n and women 50-75 years old who visited free sigmoidoscopy clinics at a health maintenance organizati

75 re reimbursement rate for screening flexible sigmoidoscopy (code 45330, $87.84).

76 ilable methods (fecal occult blood, flexible sigmoidoscopy, colonoscopy, and double contrast barium e

77 Based on sigmoidoscopy, colonoscopy, and pathology reports, occur

78 t blood testing in the past year or flexible sigmoidoscopy, colonoscopy, or barium enema in the past

79 or men, the model included a cancer-negative sigmoidoscopy/colonoscopy in the last 10 years, polyp hi

80 For women, the model included sigmoidoscopy/colonoscopy, polyp history, history of CRC

81 e incremental cost-effectiveness of flexible sigmoidoscopy compared with no evaluation or with any st

82 ness of screening with colonoscopy, flexible sigmoidoscopy, computed tomography colonography, the gua

83 INTERPRETATION: A single flexible sigmoidoscopy continues to provide substantial protectio

84 d 173 control patients (34.0%) had screening sigmoidoscopy, corresponding to an AOR of 0.50 (CI, 0.36

85 eoplasms and, if applied following screening sigmoidoscopy, could reduce the need for colonoscopy by

86 Colonoscopy, flexible sigmoidoscopy, CTC, and stool tests have differing level

87 individuals, use of colonoscopy and flexible sigmoidoscopy decreased significantly between pre- and p

88 prevalence odds ratios (ORs) and 95% CIs of sigmoidoscopy-detected, distal adenomas for quintiles of

89 g tests, including fecal occult blood tests, sigmoidoscopy, double-contrast barium enema, and colonos

90 in the NHS who had undergone colonoscopy or sigmoidoscopy during follow-up between 1980 and 1998.

91 regarding the role of colonoscopy, flexible sigmoidoscopy, endoscopic ultrasound, fecal testing and

92 dels): colonoscopy every 10 years (270 LYG); sigmoidoscopy every 10 years with annual FIT (256 LYG);

93 s of colonoscopy every 10 years, annual FIT, sigmoidoscopy every 10 years with annual FIT, and CTC ev

94 T-fecal DNA test every 3 years, and flexible sigmoidoscopy every 5 to 10 years.

95 Annual Hemoccult II and flexible sigmoidoscopy every 5 years alone were less effective.

96 Aspirin therapy in patients screened with sigmoidoscopy every 5 years and fecal occult blood testi

97 blood testing (FOBT) combined with flexible sigmoidoscopy every 5 years and using colonoscopy every

98 on of annual fecal occult blood testing with sigmoidoscopy every 5 years are viable alternatives.

99 ively expensive; annual rehydrated FOBT plus sigmoidoscopy every 5 years had an incremental CE ratio

100 screening with a sensitive FOBT, or flexible sigmoidoscopy every 5 years with a midinterval sensitive

101 testing or fecal immunochemical testing, and sigmoidoscopy every 5 years with midinterval Hemoccult S

102 s: annual fecal occult blood tests, flexible sigmoidoscopy every 5 years, or colonoscopy every 10 yea

103 ive than the combination of annual FOBT plus sigmoidoscopy every 5 years.

104 compared with annual unrehydrated FOBT plus sigmoidoscopy every 5 years.

105 older who had a negative screening flexible sigmoidoscopy examination between 1994 and 1996 and were

106 RC in the first 5 years following a negative sigmoidoscopy examination to gauge the potential benefit

107 y and less effective than FOBT plus flexible sigmoidoscopy, except in the CRC-SPIN model assuming 100

108 fecal occult-blood test with rehydration and sigmoidoscopy fails to detect advanced colonic neoplasia

109 rated fecal occult blood testing (FOBT) plus sigmoidoscopy (followed by colonoscopy if either a low-

110 Cost analysis of flexible sigmoidoscopy, followed by colonoscopy as warranted, in

111 have only reported follow-up after flexible sigmoidoscopy for a maximum of 12 years.

112 Subjects undergoing sigmoidoscopy for colorectal cancer (CRC) screening were

113 er than 50 years of age undergoing screening sigmoidoscopy for colorectal cancer.

114 er than 50 years of age undergoing screening sigmoidoscopy for CRC.

115 ons supports ongoing use of colonoscopy over sigmoidoscopy for screening examinations.

116 ts without evidence of a left-sided polyp by sigmoidoscopy, frequency-matched to cases on race and ge

117 s and controls who received colonoscopies or sigmoidoscopies from fiscal year 1997 to a date 6 months

118 Flexible sigmoidoscopy (FS) is recommended for mass screening for

119 d tomographic (CT) colonography and flexible sigmoidoscopy (FS) screening and the factors predicting

120 varying estimates of the benefit of flexible sigmoidoscopy (FS) screening for colorectal cancer (CRC)

121 ic subjects who underwent screening flexible sigmoidoscopy (FSG) within the Prostate, Lung, Colorecta

122 size of the abnormality detected at flexible sigmoidoscopy (FSG).

123 alone, but the combination of DCBE and rigid sigmoidoscopy had a sensitivity of 0.96 and a specificit

124 Fecal occult-blood testing and sigmoidoscopy have been recommended for screening for co

125 Sigmoidoscopy identified 70.3 percent of all subjects wi

126 screening with a fecal occult-blood test and sigmoidoscopy identified 75.8 percent of subjects with a

127 oidoscopy with anoscopy followed by flexible sigmoidoscopy if needed, the middle 95th percentile of t

128 sions were considered detectable by flexible sigmoidoscopy if they were in the distal colon or if the

129 hern Californians aged 50-74 years who had a sigmoidoscopy in 1991-1993.

130 udy examines the cost of performing flexible sigmoidoscopy in a primary care practice and compares th

131 y and less effective than FOBT plus flexible sigmoidoscopy in all three models in both 100% and 50% a

132 cer (T3/4 or N1) were evaluated with DRE and sigmoidoscopy in order to determine the following tumor

133 self-reported compliance rates for screening sigmoidoscopy increased by 36% (baseline, 24%; year 1, 6

134 Flexible sigmoidoscopy is a safe and practical test and, when off

135 n asymptomatic subjects undergoing screening sigmoidoscopy is advisable.

136 Sigmoidoscopy is an effective screening strategy for col

137 Case-control studies have shown that sigmoidoscopy is associated with a reduction in mortalit

138 mm or less in diameter that are detected by sigmoidoscopy is controversial.

139 se of nurse endoscopists to perform flexible sigmoidoscopy is expanding, increasing the availability

140 enomas with low-grade dysplasia are found on sigmoidoscopy is uncertain.

141 oscopy beyond the expected reach of flexible sigmoidoscopy is very low and may not justify the added

142 although current techniques (e.g., flexible sigmoidoscopy) lack the requisite sensitivity.

143 Combining fecal occult blood testing and sigmoidoscopy may decrease mortality and can increase di

144 Screening with flexible sigmoidoscopy may reduce mortality rates from colorectal

145 colorectal cancer has been suggested because sigmoidoscopy misses nearly half of persons with advance

146 Screening by sigmoidoscopy more frequently than every 5 years would l

147 (RCTs) evaluating 1-time or 2-time flexible sigmoidoscopy (n = 458,002) were associated with decreas

148 fibre intake of 33971 participants who were sigmoidoscopy-negative for polyps, with 3591 cases with

149 luated the effect of screening with flexible sigmoidoscopy on colorectal-cancer incidence and mortali

150 There was no difference between the flexible sigmoidoscopy only vs the flexible sigmoidoscopy and FOB

151 ) were diagnosed with colorectal adenomas at sigmoidoscopy or colonoscopy and histologically confirme

152 The capacity for screening with flexible sigmoidoscopy or colonoscopy depends on the proportion o

153 ng at age 50, using either FOBT and flexible sigmoidoscopy or colonoscopy in each racial or ethnic gr

154 8207 practices reported performing flexible sigmoidoscopy or colonoscopy in the United States.

155 We investigated whether sigmoidoscopy or colonoscopy is associated with a decrea

156 oor patient attendance to scheduled flexible sigmoidoscopy or colonoscopy may contribute to deficient

157 .3%) of the 276 patients underwent follow-up sigmoidoscopy or colonoscopy.

158 een the unscreened population using flexible sigmoidoscopy or colonoscopy.

159 wise prevented effectively by screening with sigmoidoscopy or colonoscopy.

160 randomized 1:1 to receive once-only flexible sigmoidoscopy or combination of once-only flexible sigmo

161 within this group, with less invasive tests (sigmoidoscopy or occult blood tests) for lower-risk pers

162 Use of cystoscopy (8.1%) and sigmoidoscopy or proctoscopy (8.6%) was significantly lo

163 were not observed among patients undergoing sigmoidoscopy or serial lower endoscopies.

164 A), fecal occult blood testing (FOBT) and/or sigmoidoscopy, or colonoscopy (COLO) in persons at avera

165 Fecal occult blood tests (FOBTs), flexible sigmoidoscopy, or colonoscopy screening beginning at age

166 computed tomographic colonography, flexible sigmoidoscopy, or colonoscopy).

167 testing (FOBT) but not colonoscopy, flexible sigmoidoscopy, or double-contrast barium enema (DCBE).

168 One-time colonoscopy, sigmoidoscopy, or fecal immunochemical test (FIT) screen

169 ecommends using a stool-based test, flexible sigmoidoscopy, or optical colonoscopy as a screening tes

170 ing strategy depends on the cost of flexible sigmoidoscopy, patient age when screening starts, and pe

171 t-based training with different results: for sigmoidoscopy, patient-based training was more effective

172 ere randomized to undergo screening flexible sigmoidoscopy performed by a nurse endoscopist or by a g

173 e incidence of complications during flexible sigmoidoscopy performed by nurse endoscopists and by gas

174 cy of missed polyps was determined by repeat sigmoidoscopy, performed by a gastroenterologist blinded

175 e incremental cost-effectiveness of flexible sigmoidoscopy plus barium enema compared with colonoscop

176 A strategy of flexible sigmoidoscopy plus barium enema yielded the greatest lif

177 cordant screening with colonoscopy, flexible sigmoidoscopy plus either sensitive unrehydrated fecal o

178 surveys to 75 individuals who underwent the sigmoidoscopy procedure.

179 Colonoscopy and sigmoidoscopy provide protection against colorectal canc

180 attitudes and quarterly review of screening sigmoidoscopy referrals using appointment logs to assess

181 0,748 colonoscopy reports, and 9767 flexible sigmoidoscopy reports to the central databank.

182 s that the time required to perform flexible sigmoidoscopy represents an opportunity cost because the

183 ent of participants, all of whom had a UCDAI sigmoidoscopy score >/=2 as read by the site investigato

184 ative Colitis Disease Activity Index (UCDAI) sigmoidoscopy score >/=2, that evaluated the efficacy of

185 friability, and a > or =1-point reduction in sigmoidoscopy score from baseline).

186 High clinical activity indices (CAI) and sigmoidoscopy scores (SS) were associated with enterobac

187 idence and mortality after a single flexible sigmoidoscopy screening and 17 years of follow-up.

188 years, randomly assigned to receive flexible sigmoidoscopy screening as part of the Prostate, Lung, C

189 tested the hypothesis that only one flexible sigmoidoscopy screening between 55 and 64 years of age c

190 ng populations and a western lifestyle.19,20 Sigmoidoscopy screening done with people aged 55-64 year

191 In Norway, once-only flexible sigmoidoscopy screening or flexible sigmoidoscopy and FO

192 first diagnosis of colorectal adenomas in a sigmoidoscopy screening population and failed to find a

193 cancer screening and only modestly improved sigmoidoscopy screening rates among patients in primary

194 Flexible Sigmoidoscopy Screening Trial (overall, 12.1%; range, 8.

195 is multicentre randomised trial (UK Flexible Sigmoidoscopy Screening Trial), done between Nov 14, 199

196 ) to an intervention group (offered flexible sigmoidoscopy screening) or a control group (not contact

197 to the intervention group (offered flexible sigmoidoscopy screening) or the control group (not conta

198 inar combined with implementation of on-site sigmoidoscopy services is an effective strategy for enha

199 inar combined with implementation of on-site sigmoidoscopy services performed by university-based gas

200 small tubular adenoma on screening flexible sigmoidoscopy should undergo colonoscopic examination of

201 Age-specific screening using sigmoidoscopy starting at ages 50 to 55 years and colono

202 tified at the time of colonoscopy (study 1), sigmoidoscopy (study 2), or at follow-up lower endoscopy

203 a net weight loss during the 10 years before sigmoidoscopy, subjects with net weight gains of 1.5-4.5

204 usion of women who reported having screening sigmoidoscopy, the relative risk for colorectal cancer s

205 For sigmoidoscopy, this association was seen for left CRC, b

206 Among patients undergoing screening sigmoidoscopy, those with single tubular adenomas of 5 m

207 ia was similar among patients with no TAs at sigmoidoscopy, those with TAs less than 1 cm in diameter

208 Sigmoidoscopy to the descending colon in the low-risk gr

209 Polyps found on sigmoidoscopy underwent biopsy, and colonoscopy was reco

210 Trends in colonoscopy and sigmoidoscopy use among Medicare beneficiaries without c

211 d Ovarian cancer screening trial of flexible sigmoidoscopy versus usual care (55-74 years old, no his

212 f whose index lesion on screening fiberoptic sigmoidoscopy was a benign adenoma.

213 Use of screening sigmoidoscopy was also significantly greater at the inte

214 Screening with flexible sigmoidoscopy was associated with a significant decrease

215 The diagnostic yield of flexible sigmoidoscopy was calculated by estimating the proportio

216 Sigmoidoscopy was defined in this study as examination o

217 olonoscopy was indicated up to age 83 years, sigmoidoscopy was indicated at age 84 years, and FIT was

218 Diet in the year before sigmoidoscopy was measured with a food frequency questio

219 Flexible sigmoidoscopy was most commonly performed for routine sc

220 Fecal occult blood testing or flexible sigmoidoscopy was ordered for 47.2% of intervention part

221 Colonoscopy and sigmoidoscopy were associated with a reduced incidence o

222 Screening colonoscopy and sigmoidoscopy were associated with reduced colorectal-ca

223 ith the performance of office-based flexible sigmoidoscopy were derived from the published literature

224 xtamucosal bacteria on biopsies taken during sigmoidoscopy were studied in a subgroup by fluorescence

225 and moderately-to-severely active disease on sigmoidoscopy) were randomized in a 2:2:2:3:3 ratio to r

226 Participants were examined by flexible sigmoidoscopy when the study began and then were randoml

227 stic sensitivity analysis comparing flexible sigmoidoscopy with anoscopy followed by flexible sigmoid

228 ce shows that periodic screening by flexible sigmoidoscopy with appropriate referral of patients with

229 ideo) was significantly related to receiving sigmoidoscopy with or without another test (odds ratio,

230 may limit the adoption of screening flexible sigmoidoscopy with or without biopsy in primary care pra

231 le classified screening since baseline as 1) sigmoidoscopy with or without other tests, 2) another te

232 IT), multitarget stool DNA testing, flexible sigmoidoscopy with or without stool testing, computed to

233 of Americans 50 years and older by flexible sigmoidoscopy with referral of subjects with adenomas to

234 nts of rectal bleeding, stool frequency, and sigmoidoscopy), with no worsening in any individual clin

235 ars of age either to screening with flexible sigmoidoscopy, with a repeat screening at 3 or 5 years,

236 sed, the physician's total cost for flexible sigmoidoscopy without biopsy was $86.86, which is simila

237 Sigmoidoscopy would have detected 21 of 24 (87.5% [CI, 6

238 For a pedigree of 5 at-risk relatives, sigmoidoscopy would have to cost less than $85.60 (profe

239 ing in both years, defined as colonoscopy or sigmoidoscopy (year 1) or fecal occult blood testing (FO

240 g (FOBT) in year 1 and FOBT, colonoscopy, or sigmoidoscopy (year 2).

241 st-effectiveness ratios ranged from flexible sigmoidoscopy yielding an increased life expectancy at r